Page 7 - Nicole Riley News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ADC Therapeutics SA: ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics SA: ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Nicole rileyDennis riedlCompany inducement planEuropean commissionCompany manual ruleCompany on linkedinCompensation committeeInducement plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomNew jerseyUnited statesLausanne biopNicole rileyCompany on linkedinCompany inducement planCompany manual ruleEuropean commissionCompensation committeeInducement planSan francisco bay area

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company’s common shares to six new employees on April 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan

New jerseyUnited statesCity ofUnited kingdomNicole rileyLausanne biopCompany on linkedinEuropean commissionCompany inducement planCompany manual ruleCompensation committeeInducement planSan francisco bay area

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21%1 year-over-year due to portfolio prioritization and operational efficiencie

New jerseyUnited statesCity ofUnited kingdomLausanne biopNicole rileyDrug administrationMitsubishi tanabe pharma corporationAmerican society of hematologyCompany onMd anderson cancer centerEuropean commissionAmerican association for cancer researchExchange commissionEuropean unionUniversity of miami

ADC Therapeutics SA: ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

ADC Therapeutics SA: ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStefan klotterNicole rileyAmerican society of hematologyCompany onCompany annual report on formUniversity of miamiDrug administrationMitsubishi tanabe pharma corporationCompany on linkedinDevelopment rd expensesEuropean commissionMd anderson cancer centerAmerican association for cancer researchData monitoring committeeExchange commission